Dr Verma has been involved in study of blood cancers such as MDS and AML in the lab and in the clinic. His work has defined the critical role of various signaling pathways (p38 MAP kinase, TGF-beta, smad2/3, IRAK and others) activation in MDS and CMML and this work has directly led to the therapeutic targeting as these pathways in clinical trials in MDS/AML (Nat Cell Bio 2019, JCI 2018, Blood 2015, 2011, JCO 2020, NEJM 2020). The FDA approval of Luspatercept in MDS was also supported by his work in the lab. Dr Verma was on the team to first define stem cell alterations in MDS/AML (Nat Med, 2018; JCI 2014, Blood 2012). Dr Verma has conducted clinical studies in blood cancers (Nat Med, 2022, Cancer Cell 2021, Can Disc, 2020; JAMA Onc 2018) that have studied the effects of COVID-19 and environmental exposures (WTC 911 disaster) on outcomes and pathogenesis. He has also been actively engaged in early phase clinical trials that are investigating novel agents for MDS and AML.